The in vitro effects of a novel vascular protectant, AGI-1067, on platelet aggregation and major receptor expression in subjects with multiple risk factors for vascular disease

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 11, Issue 3, 2006, Pages 191-196

  Serebruany, Victor ^a,c   Malinin, Alex ^a   Scott, Robert ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b AtheroGenics Inc   (United States)

^c Osler Medical Center   (United States)

Author keywords

Antioxidants; Coronary artery disease; Platelets

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANGIOTENSIN RECEPTOR ANTAGONIST; FIBRINOGEN RECEPTOR; GLYCOPROTEIN IB; GLYCOPROTEIN IB ALPHA; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY PAC 1; PROBUCOL SUCCINATE; UNCLASSIFIED DRUG;

ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DOSE RESPONSE; EX VIVO STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MALE; OXIDATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOCYTE AGGREGATION; VASCULAR DISEASE;

ADULT; ANTIGENS, CD; ANTIOXIDANTS; BALTIMORE; BIOLOGICAL MARKERS; BLOOD PLATELETS; CELL ADHESION MOLECULES; FEMALE; FLOW CYTOMETRY; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; PLATELET AGGREGATION; PLATELET MEMBRANE GLYCOPROTEINS; PROBUCOL; RECEPTORS, CELL SURFACE; RISK FACTORS; VASCULAR DISEASES;

EID: 33749574567     PISSN: 10742484     EISSN: None     Source Type: Journal    
DOI: 10.1177/1074248406290598     Document Type: Article

References (26)

1. Libby P. Changing concepts of atherogenesis. J Intern Med. 2000;247:349-358.
2. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med. 1989;320:915-924.
3. Salonen JT, Yla-Herttuala S, Yamamoto R, et al. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet. 1992;339:883-887.
4. Rodes J, Cote G, Lesperance J, et al. Prevention of restenosis after angioplasty in small coronary arteries with probucol. Circulation. 1998;97:429-436.
5. Cote G, Tardif JC, Lesperance J, et al. Effects of probucol on vascular remodeling after coronary angioplasty. Multivitamins and Protocol Study Group. Circulation. 1999;99:30-35.
6. Sundell CL, Somers PK, Meng CQ, et al. AGI-1067: a multifunctional phenolic antioxidant, lipid modulator, anti-inflammatory and antiatherosclerotic agent. J Pharmacol Exp Ther. 2003;305:1116-1123.
7. Ruggeri ZM. New insights into the mechanisms of platelet adhesion and aggregation. Semin Hematol. 1994; 31:229-239.
8. Ault KA. Flow cytometric measurement of platelet function and reticulated platelets. Ann New York Acad Sci. 1993;677:293-308.
9. Serebruany VL, Gurbel PA. The relations of major platelet receptor expression during myocardial infarction. Monitoring efficacy of GPIIb/IIIa inhibitors by measuring P-selectin? Thromb Haemost. 1999;81:314-316.
10. Serebruany VL, Gurbel PA, O'Connor CM. Platelet inhibition by sertraline and N-desmethylsertraline: a possible missing link between depression, coronary events, and mortality benefits of selective serotonin reuptake inhibitors. Pharm Res. 2001;43:453-462.
11. Serebruany VL, Malinin AI, Lowry DR, et al. Platelet inhibition by valsartan and valeryl 4-hydroxy valsartan: a possible missing link to explain benefits of angiotensin ii receptor blockers in patients after acute vascular events. J Cardiovasc Pharm. 2004;43:677-684.
12. Serebruany VL, Ordonez JV, Herzog WR, et al. Dietary coenzyme Q10 supplementation alters platelet size and inhibits human vitronectin (CD51/CD61) receptor expression. J Cardiovasc Pharm. 1997;29:16-22.
13. Kunsch C, Medford RM. Oxidative stress as a regulator of gene expression in the vasculature. Circ Res. 1999;85:753-766.
14. Li H, Cybulsky MI, Gimbrone MA Jr, Libby P. An atherogenic diet rapidly induces VCAM-1, a cytokine-regulatable mononuclear leukocyte adhesion molecule, in rabbit aortic endothelium. Arterioscler Thromb. 1993;13:197-204.
15. Gerszten RE, Lim Y, Ding HT, et al. Adhesion of monocytes to vascular cell adhesion molecule-1-transduced human endothelial cells: implications for atherogenesis. Circ Res. 1998;82:871-878.
16. Rohde LL, Lee RT, Rivero J, et al. Circulating cell adhesion molecules are correlated with ultrasound-based assessment of carotid atherosclerosis. Arterioscler Thromb Vasc Biol. 1998;18:1765-1770.
17. Blankenberg S, Rupprecht HJ, Bickel C, et al. Circulating cell adhesion molecules and death in patients with coronary artery disease. Circulation. 2001;104:1336-1342.
18. Narizhneva NV, Razorenova OV, Podrez LA, et al. Thrombospondin-1 up-regulates expression of cell adhesion molecules and promotes monocyte binding to endothelium. FASEB J. 2005;19:1158-1160.
19. van der Zijpp YJ, Foot AA, Feijen J. ICAM-1 and VCAM-1 expression by endothelial cells grown on fibronectin-coated TCPS and PS. J Biomed Mater Res A. 2003;65:51-59.
20. Gawaz M, Page S, Massberg S, et al. Transient platelet interaction induces MCP-1 production by endothelial cells via I kappa B kinase complex activation. Thromb Haemost. 2002;88:307-314.
21. Mayer K, Merfels M, Muhly-Reinholz M, et al. Omega-3 fatty acids suppress monocyte adhesion to human endothelial cells: role of endothelial PAF generation. Am J Physiol Heart Circ Physiol. 2002;283:H811-H818.
22. Rinder HM, Bonan JL, Rinder CS, Ault KA, Smith BR. Dynamics of leukocyte-platelet adhesion in whole blood. Blood. 1991;78:1730-1737.
23. Weyrich AS, Elstad MR, McEver RP, et al. Activated platelets signal chemokine synthesis by human monocytes. J Clin Invest. 1996;97:1525-1534.
24. Selley ML, Bartlett MR, Czeti AL, Ardlie NG. The role of (E)-4-hydroxy-2-nonenal in platelet activation by low-density lipoprotein and iron. Atherosclerosis. 1998;140:105-112.
25. Simons LA, Balasubramaniam S, Beins DM. Metabolic studies with probucol in hypercholesterolaemia. Atherosclerosis. 1981;40:299-308.
26. Nomura S, Takahashi N, Inami N, et al. Probucol and ticlopidine: effect on platelet and monocyte activation markers in hyperlipidemic patients with and without type 2 diabetes. Atherosclerosis. 2004;174:329-335.